Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $92.37 which represents a slight increase of $0.36 or 0.39% from the prior close of $92.01. The stock opened at $92.59 and ...

Gilead (GILD) and Terray Therapeutics announced that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%.

Mount Gilead traveled to Cardington for a rivalry girls basketball game in the Knox Morrow Athletic Conference on Friday ...

Gilead Sciences Inc. closed $7.02 below its 52-week high ($98.90), which the company achieved on November 11th.